SIKE1

Summary

SIKE1 (suppressor of IKBKE 1, HGNC:26119) is a protein-coding gene on chromosome 1p13.2, encoding Suppressor of IKBKE 1 (Q9BRV8). Physiological suppressor of IKK-epsilon and TBK1 that plays an inhibitory role in virus- and TLR3-triggered IRF3.

SIKE interacts with IKK-epsilon (IKBKE; MIM 605048) and TBK1 (MIM 604834) and acts as a suppressor of TLR3 (MIM 603029) and virus-triggered interferon activation pathways (Huang et al., 2005 [PubMed 16281057]).

Source: NCBI Gene 80143 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 32 total
• MANE Select transcript: NM_025073

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26119
Approved symbol	SIKE1
Name	suppressor of IKBKE 1
Location	1p13.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ21168, SIKE
Ensembl gene	ENSG00000052723
Ensembl biotype	protein_coding
OMIM	611656
Entrez	80143

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 7 protein_coding_CDS_not_defined, 5 protein_coding, 1 retained_intron

ENST00000060969, ENST00000369524, ENST00000369528, ENST00000462123, ENST00000466657, ENST00000471969, ENST00000474562, ENST00000475335, ENST00000506320, ENST00000510745, ENST00000888003, ENST00000888004, ENST00000888005

RefSeq mRNA: 2 — MANE Select: NM_025073 NM_001102396, NM_025073

CCDS: CCDS41371, CCDS878

Canonical transcript exons

ENST00000060969 — 5 exons

Exon	Start	End
ENSE00001927894	114780449	114780685
ENSE00003498049	114780110	114780215
ENSE00003582002	114779142	114779284
ENSE00003670208	114776346	114776459
ENSE00003903604	114769479	114774372

Expression profiles

Bgee: expression breadth ubiquitous, 275 present calls, max score 96.50.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.3790 / max 182.1816, expressed in 1821 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
13972	33.0512	1820
13971	1.3278	680

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	96.50	gold quality
adrenal tissue	UBERON:0018303	93.38	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.61	gold quality
stromal cell of endometrium	CL:0002255	90.06	gold quality
gastrocnemius	UBERON:0001388	89.67	gold quality
oocyte	CL:0000023	89.51	gold quality
muscle of leg	UBERON:0001383	89.45	gold quality
secondary oocyte	CL:0000655	88.14	gold quality
palpebral conjunctiva	UBERON:0001812	88.05	gold quality
calcaneal tendon	UBERON:0003701	87.66	gold quality
germinal epithelium of ovary	UBERON:0001304	87.58	gold quality
colonic epithelium	UBERON:0000397	87.40	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.71	gold quality
endometrium	UBERON:0001295	86.61	gold quality
islet of Langerhans	UBERON:0000006	86.37	gold quality
tonsil	UBERON:0002372	86.25	gold quality
heart left ventricle	UBERON:0002084	86.09	gold quality
right lobe of liver	UBERON:0001114	85.94	gold quality
apex of heart	UBERON:0002098	85.56	gold quality
cardiac ventricle	UBERON:0002082	85.51	gold quality
lymph node	UBERON:0000029	85.48	gold quality
eye	UBERON:0000970	85.37	gold quality
right atrium auricular region	UBERON:0006631	85.28	gold quality
medial globus pallidus	UBERON:0002477	85.16	gold quality
skeletal muscle organ	UBERON:0014892	85.15	gold quality
muscle organ	UBERON:0001630	85.14	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.11	gold quality
tendon	UBERON:0000043	84.77	gold quality
monocyte	CL:0000576	84.64	gold quality
leukocyte	CL:0000738	84.57	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

201 targeting SIKE1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6867-5P	100.00	82.21	3464

Literature-anchored findings (GeneRIF, showing 4)

• Overexpression of SIKE inhibits virus- and Toll-like receptor 3-triggered interferon-stimulated response elements (ISRE) but not NF-kappa B activation. (PMID:16281057)
• Data indicate that suppressor of IKKepsilon (SIKE) inhibits TANK-binding kinase 1 (TBK1)-mediated phosphorylation of interferon regulatory factor 3 (IRF3), which is essential to type I interferon production. (PMID:23649622)
• SIKE, a negative regulator of the interferon pathway, attenuates pathological cardiac hypertrophy. (PMID:27249321)
• mRNA expression of individual inhibitory kappaB kinases and SIKE are associated with unique prognostic significance and may act as valuable prognostic biomarkers and potential targets for future therapeutic interventions in gastric cancer. (PMID:30487159)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	sike1	ENSDARG00000102199
mus_musculus	Sike1	ENSMUSG00000027854
rattus_norvegicus	Sike1	ENSRNOG00000017502
drosophila_melanogaster	Fgop2	FBGN0031871
caenorhabditis_elegans		WBGENE00007579

Paralogs (1): FGFR1OP2 (ENSG00000111790)

Protein

Protein identifiers

Suppressor of IKBKE 1 — Q9BRV8 (reviewed: Q9BRV8)

Alternative names: Suppressor of IKK-epsilon

All UniProt accessions (1): Q9BRV8

UniProt curated annotations — full annotation on UniProt →

Function. Physiological suppressor of IKK-epsilon and TBK1 that plays an inhibitory role in virus- and TLR3-triggered IRF3. Inhibits TLR3-mediated activation of interferon-stimulated response elements (ISRE) and the IFN-beta promoter. May act by disrupting the interactions of IKBKE or TBK1 with TICAM1/TRIF, IRF3 and RIGI. Does not inhibit NF-kappa-B activation pathways. Associates with the striatin-interacting phosphatase and kinase (STRIPAK) core complex, forming the extended (SIKE1:SLMAP)STRIPAK complex. The (SIKE1:SLMAP)STRIPAK complex dephosphorylates STK3 leading to the inhibition of Hippo signaling and the control of cell growth.

Subunit / interactions. Interacts with IKBKE and TBK1 via its coiled coil region. Interaction with TBK1 is disrupted upon viral infection or TLR3 stimulation. Interacts with CDC42BPB. Interacts with SIKE1 which mediates association with the STRIPAK core complex composed of PP2A catalytic and scaffolding subunits, the striatins (PP2A regulatory subunits), the striatin-associated proteins MOB4, STRIP1 and STRIP2, PDCD10 and members of the STE20 kinases, such as STK24 and STK26.

Subcellular location. Cytoplasm.

Tissue specificity. Widely expressed. Expressed in brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung and leukocytes. Present in all cell lines tested (at protein level).

Similarity. Belongs to the SIKE family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BRV8-1	1	yes
Q9BRV8-2	2

RefSeq proteins (2): NP_001095866, NP_079349* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008555	SIKE	Family

Pfam: PF05769

UniProt features (19 total): mutagenesis site 10, sequence conflict 3, coiled-coil region 2, helix 2, chain 1, splice variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6AKK	X-RAY DIFFRACTION	1.5
6AKL	X-RAY DIFFRACTION	1.75
6AKM	X-RAY DIFFRACTION	2.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BRV8-F1	85.88	0.63

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (10):

Position	Phenotype
96	loss of (sike1:slmap)stripak complex formation; when associated with a-109.
97	loss of (sike1:slmap)stripak complex formation.
101	loss of (sike1:slmap)stripak complex formation.
109	loss of (sike1:slmap)stripak complex formation; when associated with a-109.
15	loss of interaction with slmap.
19	loss of interaction with slmap.
36	loss of interaction with slmap.
43	no effect on interaction with slmap.
90	loss of (sike1:slmap)stripak complex formation.
94	loss of (sike1:slmap)stripak complex formation.

Function

Pathways and Gene Ontology

Reactome pathways

15 pathways

ID	Pathway
R-HSA-918233	TRAF3-dependent IRF activation pathway
R-HSA-933541	TRAF6 mediated IRF7 activation
R-HSA-9692916	SARS-CoV-1 activates/modulates innate immune responses
R-HSA-9705671	SARS-CoV-2 activates/modulates innate and adaptive immune responses
R-HSA-1643685	Disease
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta
R-HSA-5663205	Infectious disease
R-HSA-9678108	SARS-CoV-1 Infection
R-HSA-9679506	SARS-CoV Infections
R-HSA-9692914	SARS-CoV-1-host interactions
R-HSA-9694516	SARS-CoV-2 Infection
R-HSA-9705683	SARS-CoV-2-host interactions
R-HSA-9824446	Viral Infection Pathways

MSigDB gene sets: 200 (showing top): REACTOME_DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA, GSE45365_NK_CELL_VS_CD8_TCELL_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, REACTOME_INNATE_IMMUNE_SYSTEM, TGCGCANK_UNKNOWN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN, BROWNE_HCMV_INFECTION_16HR_UP, GOBP_HIPPO_SIGNALING, GOMF_GTPASE_BINDING, GGGTGGRR_PAX4_03, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, PUJANA_CHEK2_PCC_NETWORK, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM6, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP

GO Biological Process (1): negative regulation of hippo signaling (GO:0035331)

GO Molecular Function (4): protein kinase binding (GO:0019901), protein-macromolecule adaptor activity (GO:0030674), small GTPase binding (GO:0031267), protein binding (GO:0005515)

GO Cellular Component (3): cytosol (GO:0005829), FAR/SIN/STRIPAK complex (GO:0090443), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-11 pathways:

Category	Pathways
DDX58/IFIH1-mediated induction of interferon-alpha/beta	2
SARS-CoV Infections	2
SARS-CoV-1-host interactions	1
SARS-CoV-2-host interactions	1
Immune System	1
Innate Immune System	1
Disease	1
Viral Infection Pathways	1
SARS-CoV-1 Infection	1
SARS-CoV-2 Infection	1
Infectious disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
hippo signaling	1
regulation of hippo signaling	1
negative regulation of intracellular signal transduction	1
kinase binding	1
protein binding	1
molecular adaptor activity	1
GTPase binding	1
binding	1
cytoplasm	1
protein-containing complex	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

766 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SIKE1	SLMAP	Q14BN4	979
SIKE1	IKBKE	Q14164	904
SIKE1	TBK1	Q9UHD2	891
SIKE1	MOB4	Q9Y3A3	794
SIKE1	STRIP2	Q9ULQ0	782
SIKE1	STRN	O43815	768
SIKE1	STRIP1	Q5VSL9	763
SIKE1	EMD	P50402	729
SIKE1	PDCD10	Q9BUL8	719
SIKE1	CTTNBP2NL	Q9P2B4	718
SIKE1	RIGI	O95786	701
SIKE1	STK26	Q9P289	692
SIKE1	CTTNBP2	Q8WZ74	639
SIKE1	IRF3	Q14653	624
SIKE1	STRN3	Q13033	589

IntAct

110 interactions, top by confidence:

A	B	Type	Score
PDCD10	STK25	psi-mi:“MI:0914”(association)	0.980
STK25	STRN	psi-mi:“MI:0914”(association)	0.900
STK24	STK25	psi-mi:“MI:0914”(association)	0.890
PPP2R1A	STRN	psi-mi:“MI:0914”(association)	0.880
PPP2R1A	STRN	psi-mi:“MI:2364”(proximity)	0.880
STRN3	STK25	psi-mi:“MI:0914”(association)	0.880
STRN3	STRN	psi-mi:“MI:0914”(association)	0.880
STRN3	STRN	psi-mi:“MI:2364”(proximity)	0.880
STK24	STRN	psi-mi:“MI:0914”(association)	0.870
STRIP1	PPP2CB	psi-mi:“MI:0914”(association)	0.870
STK26	STRN	psi-mi:“MI:0914”(association)	0.860
STRIP1	STK25	psi-mi:“MI:0914”(association)	0.840
MOB4	STRN	psi-mi:“MI:0914”(association)	0.790
PPP2CB	STRN	psi-mi:“MI:0914”(association)	0.790
STK26	STK25	psi-mi:“MI:0914”(association)	0.790
SIKE1	SLMAP	psi-mi:“MI:0914”(association)	0.770
STRN4	STRN	psi-mi:“MI:0914”(association)	0.730
MOB4	STK25	psi-mi:“MI:0914”(association)	0.730
SIKE1	STRN	psi-mi:“MI:0914”(association)	0.730
PSMC5	PSMD11	psi-mi:“MI:0914”(association)	0.730
PPP2CB	CEP43	psi-mi:“MI:0914”(association)	0.730
SLMAP	STRN	psi-mi:“MI:0914”(association)	0.710
SLMAP	STRN	psi-mi:“MI:2364”(proximity)	0.710
STRN3	SIKE1	psi-mi:“MI:0915”(physical association)	0.670

BioGRID (151): SIKE1 (Affinity Capture-MS), SIKE1 (Affinity Capture-MS), SIKE1 (Affinity Capture-MS), SIKE1 (Affinity Capture-MS), SIKE1 (Affinity Capture-MS), BTD (Affinity Capture-MS), ICT1 (Affinity Capture-MS), PPP2CA (Affinity Capture-MS), PPP2R1A (Affinity Capture-MS), PPP2R1B (Affinity Capture-MS), STRN (Affinity Capture-MS), TTC1 (Affinity Capture-MS), SLMAP (Affinity Capture-MS), ELL (Affinity Capture-MS), STK24 (Affinity Capture-MS)

ESM2 similar proteins: A1A5P5, A2BDR7, A2CEM9, A2XW69, A4IGC3, A8KB59, B0WPU9, O76878, P16568, P34609, P70302, P84903, Q08C53, Q0V9T6, Q0VCF3, Q13586, Q17AF4, Q29EP6, Q2KI89, Q2T9W6, Q58CP9, Q5FWT9, Q5I033, Q5R629, Q5R8J5, Q6DF11, Q6DIX6, Q6GP65, Q6NRB0, Q6ZP65, Q78PB6, Q7PWT9, Q7T338, Q7XU27, Q7Z3E5, Q8AVR2, Q8BIJ7, Q8K4I6, Q8MJK1, Q91WK0

Diamond homologs: O02197, Q0VCF3, Q5FWT9, Q5I033, Q5R8J5, Q6DF11, Q6GP65, Q8AVR2, Q9BRV8, Q9CPR7, Q5R561, Q5ZKJ4, Q6TA25, Q7T338, Q9CRA9, Q9NVK5, Q9VM65

SIGNOR signaling

7 interactions.

A	Effect	B	Mechanism
TBK1	“up-regulates quantity”	SIKE1	phosphorylation
TBK1	“down-regulates quantity”	SIKE1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 67 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Degradation of beta-catenin by the destruction complex	5	25.4×	2e-04
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal	5	17.1×	2e-04
RHO GTPases Activate Formins	6	13.7×	2e-04
EML4 and NUDC in mitotic spindle formation	5	13.7×	5e-04
Resolution of Sister Chromatid Cohesion	5	12.7×	6e-04
Separation of Sister Chromatids	7	12.5×	2e-04
Mitotic Prometaphase	6	12.2×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of hippo signaling	7	91.0×	2e-10
intracellular signal transduction	8	5.7×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

32 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	17
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

754 predictions. Top by Δscore:

Variant	Effect	Δscore
1:114774368:TCAAG:T	acceptor_gain	1.0000
1:114774369:CAAG:C	acceptor_gain	1.0000
1:114774369:CAAGC:C	acceptor_gain	1.0000
1:114774371:AG:A	acceptor_gain	1.0000
1:114774372:GC:G	acceptor_loss	1.0000
1:114774373:C:CC	acceptor_gain	1.0000
1:114776377:CAAAA:C	donor_gain	1.0000
1:114779140:A:AC	donor_gain	1.0000
1:114779140:ACTG:A	donor_gain	1.0000
1:114779141:C:CC	donor_gain	1.0000
1:114779141:CTG:C	donor_gain	1.0000
1:114779141:CTGC:C	donor_gain	1.0000
1:114779280:TAGCT:T	acceptor_gain	1.0000
1:114779282:GCTC:G	acceptor_loss	1.0000
1:114779283:CT:C	acceptor_gain	1.0000
1:114779283:CTCTG:C	acceptor_loss	1.0000
1:114779285:C:CC	acceptor_gain	1.0000
1:114779286:T:A	acceptor_loss	1.0000
1:114780436:CCCT:C	donor_gain	1.0000
1:114780483:G:C	donor_gain	1.0000
1:114774370:AAG:A	acceptor_gain	0.9900
1:114774374:T:A	acceptor_loss	0.9900
1:114774659:T:A	donor_gain	0.9900
1:114776340:TCTTA:T	donor_loss	0.9900
1:114776342:TTA:T	donor_loss	0.9900
1:114776456:TTTC:T	acceptor_gain	0.9900
1:114776458:TC:T	acceptor_gain	0.9900
1:114776459:CC:C	acceptor_gain	0.9900
1:114776461:T:A	acceptor_loss	0.9900
1:114776471:T:TC	acceptor_gain	0.9900

AlphaMissense

1374 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:114779224:C:G	R109P	0.999
1:114779235:C:A	M105I	0.999
1:114779235:C:G	M105I	0.999
1:114779235:C:T	M105I	0.999
1:114779242:A:G	L103P	0.999
1:114779281:A:G	L90P	0.999
1:114780552:A:G	L19P	0.999
1:114774356:A:G	L180P	0.998
1:114780531:G:T	A26D	0.998
1:114780564:A:G	L15P	0.998
1:114780573:G:T	A12D	0.998
1:114780574:C:G	A12P	0.998
1:114780116:T:C	N87D	0.997
1:114780532:C:G	A26P	0.997
1:114776405:C:G	A155P	0.996
1:114779224:C:A	R109L	0.996
1:114779228:A:C	Y108D	0.996
1:114779239:A:T	I104N	0.996
1:114779252:C:G	A100P	0.996
1:114780127:A:G	L83S	0.996
1:114780582:A:G	L9P	0.996
1:114779225:G:C	R109G	0.995
1:114779236:A:G	M105T	0.995
1:114779260:T:G	H97P	0.995
1:114780136:A:G	I80T	0.995
1:114780522:A:G	L29P	0.995
1:114779251:G:T	A100D	0.994
1:114779227:T:G	Y108S	0.993
1:114779239:A:C	I104S	0.993
1:114779261:G:C	H97D	0.993

dbSNP variants (sampled 300 via entrez): RS1000734589 (1:114778078 A>G), RS1000786880 (1:114777678 A>G), RS1000919358 (1:114771126 T>C,G), RS1001180935 (1:114776953 G>A), RS1001421391 (1:114777203 TAAC>T), RS1001457530 (1:114780913 A>G), RS1002407640 (1:114779406 G>A,T), RS1002856116 (1:114775401 A>G), RS1003008765 (1:114769023 C>T), RS1003134120 (1:114782498 T>C,G), RS1003245111 (1:114780930 TG>T), RS1003868259 (1:114775450 C>A), RS1003904309 (1:114771574 T>C), RS1004759596 (1:114780639 T>C), RS1004767886 (1:114776725 C>A)

Disease associations

OMIM: gene MIM:611656 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90000047_15	Age at first sexual intercourse	1.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009749	age at first sexual intercourse measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Smoke	decreases expression, increases abundance	2
geldanamycin	increases expression	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases abundance, increases expression	1
cobaltous chloride	increases expression	1
butyraldehyde	decreases expression	1
manganese chloride	increases expression, increases abundance	1
torcetrapib	increases expression	1
jinfukang	decreases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	decreases expression	1
Vorinostat	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	increases abundance, increases expression	1
Doxorubicin	decreases expression	1
Endosulfan	decreases expression	1
Manganese	increases abundance, increases expression	1
Methotrexate	increases expression	1
Silicon Dioxide	decreases expression	1
Theophylline	increases expression	1
Thimerosal	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	increases expression	1
Cyclosporine	decreases expression	1
Lactic Acid	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2FD	Abcam HeLa SIKE1 KO	Cancer cell line	Female
CVCL_TL17	HAP1 SIKE1 (-) 1	Cancer cell line	Male
CVCL_TL18	HAP1 SIKE1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.